SUPERNUS PHARMACEUTICALS INC (SUPN) Stock Price, Quote, News and Overview
NASDAQ:SUPN - Nasdaq - US8684591089 - Common Stock - Currency: USD
SUPN Quote, Performance and Key Statistics
31.65
-0.09 (-0.28%)
The current stock price of SUPN is 31.65 USD. In the past month the price decreased by -15.28%. In the past year, price increased by 1.87%.
SUPN Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 70.08 | 864.89B | ||
| JNJ | JOHNSON & JOHNSON | 16.56 | 398.27B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 27.26 | 388.42B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 21.34 | 239.56B | ||
| MRK | MERCK & CO. INC. | 12.12 | 234.14B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14.03 | 220.06B | ||
| PFE | PFIZER INC | 8.28 | 145.92B | ||
| SNY | SANOFI-ADR | 14.39 | 144.66B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 52.14 | 120.56B | ||
| GSK | GSK PLC-SPON ADR | 8.14 | 78.42B | ||
| ZTS | ZOETIS INC | 28.7 | 76.65B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 34.49 | 47.02B |
Related stock screener links
About SUPN
Company Profile
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. The company is headquartered in Rockville, Maryland and currently employs 652 full-time employees. The company went IPO on 2010-12-28. The firm is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson’s Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The firm is also developing a range of novel CNS product candidates, including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders. Its commercial products, including Qelbree (viloxazine), GOCOVRI (amantadine), Oxtellar XR (oxcarbazepine), Trokendi XR (topiramate), APOKYN (apomorphine hydrochloride injection) and others. Qelbree (viloxazine) is a novel non-stimulant product indicated for the treatment of ADHD.
Company Info
SUPERNUS PHARMACEUTICALS INC
9715 Key West Avenue
Rockville MARYLAND 20850 US
CEO: JACK A. KHATTAR
Employees: 652
Company Website: https://www.supernus.com
Investor Relations: https://ir.supernus.com/
Phone: 13018382500
SUPERNUS PHARMACEUTICALS INC / SUPN FAQ
What is the stock price of SUPERNUS PHARMACEUTICALS INC today?
The current stock price of SUPN is 31.65 USD. The price decreased by -0.28% in the last trading session.
What is the ticker symbol for SUPERNUS PHARMACEUTICALS INC stock?
The exchange symbol of SUPERNUS PHARMACEUTICALS INC is SUPN and it is listed on the Nasdaq exchange.
On which exchange is SUPN stock listed?
SUPN stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for SUPERNUS PHARMACEUTICALS INC stock?
11 analysts have analysed SUPN and the average price target is 39.58 USD. This implies a price increase of 25.04% is expected in the next year compared to the current price of 31.65. Check the SUPERNUS PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is SUPERNUS PHARMACEUTICALS INC worth?
SUPERNUS PHARMACEUTICALS INC (SUPN) has a market capitalization of 1.75B USD. This makes SUPN a Small Cap stock.
How many employees does SUPERNUS PHARMACEUTICALS INC have?
SUPERNUS PHARMACEUTICALS INC (SUPN) currently has 652 employees.
What are the support and resistance levels for SUPERNUS PHARMACEUTICALS INC (SUPN) stock?
SUPERNUS PHARMACEUTICALS INC (SUPN) has a support level at 31.64 and a resistance level at 38.73. Check the full technical report for a detailed analysis of SUPN support and resistance levels.
Is SUPERNUS PHARMACEUTICALS INC (SUPN) expected to grow?
The Revenue of SUPERNUS PHARMACEUTICALS INC (SUPN) is expected to decline by -3.22% in the next year. Check the estimates tab for more information on the SUPN EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy SUPERNUS PHARMACEUTICALS INC (SUPN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of SUPN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of SUPN, evaluating the profitability, health, valuation and growth aspects
- SUPERNUS PHARMACEUTICALS INC (SUPN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- SUPERNUS PHARMACEUTICALS INC (SUPN) Sales and EPS estimates to see what analysts future expectations are.
- SUPERNUS PHARMACEUTICALS INC (SUPN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- SUPERNUS PHARMACEUTICALS INC (SUPN) Insider and Institutional Ownership to learn about the owners and their transactions.
- SUPERNUS PHARMACEUTICALS INC (SUPN) Stock Chart to make your own analysis
- SUPERNUS PHARMACEUTICALS INC (SUPN) Latest news and press-releases to stay up to date.
Does SUPERNUS PHARMACEUTICALS INC (SUPN) stock pay dividends?
SUPN does not pay a dividend.
When does SUPERNUS PHARMACEUTICALS INC (SUPN) report earnings?
SUPERNUS PHARMACEUTICALS INC (SUPN) will report earnings on 2025-05-06, after the market close.
What is the Price/Earnings (PE) ratio of SUPERNUS PHARMACEUTICALS INC (SUPN)?
The PE ratio for SUPERNUS PHARMACEUTICALS INC (SUPN) is 12.46. This is based on the reported non-GAAP earnings per share of 2.54 and the current share price of 31.65 USD. Check the full fundamental report for a full analysis of the valuation metrics for SUPN.
What is the Short Interest ratio of SUPERNUS PHARMACEUTICALS INC (SUPN) stock?
The outstanding short interest for SUPERNUS PHARMACEUTICALS INC (SUPN) is 10.91% of its float. Check the ownership tab for more information on the SUPN short interest.
SUPN Technical Analysis
SUPN Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to SUPN. SUPN scores excellent points on both the profitability and health parts. This is a solid base for a good stock.
SUPN Financial Highlights
Over the last trailing twelve months SUPN reported a non-GAAP Earnings per Share(EPS) of 2.54. The EPS increased by 81.43% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 11.16% | ||
| ROA | 5.4% | ||
| ROE | 7.13% | ||
| Debt/Equity | 0 |
SUPN Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 78% to SUPN. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of -22.63% and a revenue growth -3.22% for SUPN